Challenges for Developing PET Tracers: Isotopes, Chemistry, and Regulatory Aspects.

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Neuroscience

Background:

• Positron Emission Tomography (PET) radiotracer development is constrained by the short half-lives of common radionuclides, primarily carbon-11 and fluorine-18.
• Despite these limitations, significant advancements in radiosynthetic methods have occurred over the past decade.

Purpose of the Study:

• To review recent developments in PET radiochemistry that facilitate radiotracer development.
• To discuss the application of these principles in central nervous system (CNS) research.
• To review the current regulatory landscape for human PET imaging studies.

Main Methods:

• Review of recent literature on PET radiochemistry and radiosynthesis.
• Discussion of established principles in PET radiotracer development.
• Analysis of regulatory requirements for clinical PET imaging.

Main Results:

• Advances in radiosynthetic methods are poised to increase the number of radiotracers transitioning from research to clinical PET studies.
• Specific applications of PET radiotracer development principles in CNS research are highlighted.
• An overview of current regulatory requirements for human imaging studies is provided.

Conclusions:

• Innovations in PET radiochemistry are overcoming limitations posed by short-lived radionuclides.
• These advancements will likely accelerate the clinical translation of novel PET radiotracers, particularly for CNS applications.
• Understanding and navigating regulatory requirements is crucial for successful clinical implementation.